Axsome Therapeutics Enters into $20 Million Term Loan Agreement with Silicon Valley Bank
November 10, 2016 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Nov. 10, 2016 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics Announces Publication of Research Showing AXS-02 Inhibits Pain in Animal Model of Complex Regional Pain Syndrome
October 04, 2016 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Oct. 04, 2016 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics to Present at Upcoming Investor Conferences
September 06, 2016 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Sept. 06, 2016 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics to Present at the 2016 JMP Securities Life Sciences Conference
June 13, 2016 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, June 13, 2016 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics Receives FDA Fast Track Designation for AXS-02 for the Treatment of the Pain of Knee Osteoarthritis Associated with Bone Marrow Lesions
May 03, 2016 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, May 03, 2016 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics Initiates Phase 3 Study of AXS-02 for Knee Osteoarthritis Associated with Bone Marrow Lesions
March 28, 2016 07:00 ET
|
Axsome Therapeutics, Inc.
First Patient Enrolled in the COAST-1 StudyNon-Opioid, Oral, Targeted, Potentially First-in-Class Mechanism for PainNovel Biomarker-Based Approach for the Treatment of Knee Osteoarthritis...
Axsome Therapeutics Receives New U.S. Patent Covering AXS-02 for the Treatment of Complex Regional Pain Syndrome
March 15, 2016 07:00 ET
|
Axsome Therapeutics, Inc.
Provides Patent Protection for AXS-02 into 2033Covers Uses of Oral Zoledronic Acid for Complex Regional Pain SyndromeRepresents the 19th Issued Patent Covering AXS-02 or Related Compounds NEW YORK,...
Axsome Therapeutics to Present at the 2016 BIO CEO & Investor Conference
February 01, 2016 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Feb. 01, 2016 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical stage biopharmaceutical company developing novel therapies for the management of central nervous...